Protagenic Starts Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

 Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026

Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced completion of first dose injection for all study subjects in the multiple-dose portion of its ongoing Phase I clinical trial of PT00114. The company expects to complete dosing by the end of August, with topline safety data anticipated by the end of September, supporting advancement into Phase 2 efficacy studies planned for the first quarter of 2026.

PT00114 is the first investigational therapy based on Teneurin C-terminus Associated Peptide (TCAP), a naturally occurring brain hormone localized in the amygdala and hippocampus that regulates stress and emotional balance. Unlike existing therapies that blunt symptoms, PT00114 is thought to directly modulate the brain's maladaptive responses to stress-offering a differentiated approach to treating anxiety, depression, addiction, and Post Traumatic Stress Disorder (PTSD).

Current treatments leave more than half of patients without adequate relief and are burdened by significant side effects.

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/protagenic-therapeutics-advances-pt00114-into-multiple-dose-phase-1-t-1063654